IBio Price Target Announced at $3.60/Share by Brookline Capital
IBio Analyst Ratings
IBio Analyst Ratings
IBio Analyst Ratings
Chardan Research Starts IBio With Buy Rating, $5 Price Target
IBio Analyst Ratings
IBio Analyst Ratings
Cantor Fitzgerald Downgrades IBio to Neutral, Lowers Price Target to $0.17
No Data